Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Eur Radiol
    November 2025
  1. YAN J, Jiang N, Wu S, Ren R, et al
    MRI evaluation of obturator internus muscle: its relationship with body composition and prognostic implications in prostate cancer patients undergoing ADT.
    Eur Radiol. 2025 Nov 27. doi: 10.1007/s00330-025-12156.
    >> Share

  2. FORREST AB, Kruse DE, Calio B, Ivey MC, et al
    Detection of clinically significant prostate cancer using targeted MRI-informed microultrasound biopsy.
    Eur Radiol. 2025 Nov 22. doi: 10.1007/s00330-025-12136.
    >> Share

  3. BARENTSZ JO, Ahmed HU, Miszczyk M, Catalano C, et al
    ESR Bridges: early-stage prostate cancer: new developments in imaging and treatment-a multidisciplinary view.
    Eur Radiol. 2025 Nov 7. doi: 10.1007/s00330-025-12125.
    >> Share

  4. VAN DEN KROONENBERG DL, Delberghe F, Jager A, Postema AW, et al
    Evaluation of an artificial intelligence model based on multiparametric transrectal ultrasound for localizing clinically significant prostate cancer by simulation of targeted biopsies.
    Eur Radiol. 2025 Nov 6. doi: 10.1007/s00330-025-12114.
    >> Share

  5. WOO S, Russo L, Withey SJ, Dehghanpour A, et al
    ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer.
    Eur Radiol. 2025 Nov 5. doi: 10.1007/s00330-025-12089.
    >> Share

  6. CHENG Y, Shen L, Liao Q, Qin J, et al
    Multi-reader evaluation of the prostate imaging quality score system version 2 (PI-QUAL V2) and its clinical application.
    Eur Radiol. 2025;35:7027-7039.
    >> Share

  7. IVEY MC, Deivasigamani S, Kotamarti S, Mottaghi M, et al
    External validation of inter-reader reliability of the Prostate Imaging after Focal Ablation (PI-FAB) scoring system following focal cryoablation and focal high-intensity focused ultrasound.
    Eur Radiol. 2025;35:7004-7012.
    >> Share

    October 2025
  8. PONSIGLIONE A, Cimadamore A, Girometti R
    Unmasking "unconventional" prostate cancer histologies: A real diagnostic challenge?
    Eur Radiol. 2025 Oct 31. doi: 10.1007/s00330-025-12066.
    >> Share

  9. RATA M, Tunariu N, Jiang Y, Hughes J, et al
    Serial T(1) and T(2) measurements of metastatic bone lesions in prostate cancer patients: MR fingerprinting vs conventional MRI.
    Eur Radiol. 2025 Oct 24. doi: 10.1007/s00330-025-12071.
    >> Share

  10. GIROMETTI R, Peruzzi V, Clauser P, Potsch N, et al
    Diffusion levels for quantitative assessment of the apparent diffusion coefficient value in prostate MRI: a proof-of-concept bicentric study.
    Eur Radiol. 2025;35:6171-6182.
    >> Share

    September 2025
  11. AGROTIS G, Ursprung S, Schoots IG
    Personalised prostate MRI: tailoring contrast medium use in an era of increasing demand.
    Eur Radiol. 2025;35:5710-5713.
    >> Share

  12. SYER T, Carmo B, Sanmugalingam N, Lawson B, et al
    On-table monitoring of prostate MRI could enable tailored utilisation of gadolinium contrast.
    Eur Radiol. 2025;35:5701-5709.
    >> Share

    August 2025
  13. THORLEY N, Parry T, Giganti F, Kopcke D, et al
    Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE study).
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11837.
    >> Share

  14. NAVES AA, de Lion Gouvea G, Machado CVB, Colli LM, et al
    Reply to the Letter to the Editor: MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11897.
    >> Share

  15. KEIVANY MR, Zare H
    Letter to the Editor: MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11896.
    >> Share

  16. JOHNSON PM, Tong A, Ginocchio L, Del Hoyo JL, et al
    External evaluation of an open-source deep learning model for prostate cancer detection on bi-parametric MRI.
    Eur Radiol. 2025 Aug 3. doi: 10.1007/s00330-025-11865.
    >> Share

    July 2025
  17. NAVES AA, de Lion Gouvea G, Machado CVB, Colli LM, et al
    Reply to the Letter to the Editor: Translating MRI-detected extranodal extension into clinical practice in prostate cancer-practical considerations and future directions.
    Eur Radiol. 2025 Jul 11. doi: 10.1007/s00330-025-11811.
    >> Share

  18. CHEN S, Fang Y, Cheng B
    Letter to the Editor: Translating MRI-detected extranodal extension into clinical practice in prostate cancer: practical considerations and future directions.
    Eur Radiol. 2025 Jul 11. doi: 10.1007/s00330-025-11810.
    >> Share

  19. WOO S, Becker AS, Leithner D, Mayerhoefer ME, et al
    Discordance between prostate MRI and PSMA-PET/CT: the next big challenge for primary prostate tumor assessment?
    Eur Radiol. 2025;35:4043-4054.
    >> Share

    June 2025
  20. FRANSEN SJ, Bosma JS, van Lohuizen Q, Roest C, et al
    Simulating workload reduction with an AI-based prostate cancer detection pathway using a prediction uncertainty metric.
    Eur Radiol. 2025 Jun 7. doi: 10.1007/s00330-025-11727.
    >> Share

  21. LEE KL, Caglic I, Liao PH, Kessler DA, et al
    PI-QUAL version 2 image quality categorisation and inter-reader agreement compared to version 1.
    Eur Radiol. 2025;35:3096-3104.
    >> Share

    April 2025
  22. CARLETTI F, Maggi M, Fazekas T, Rajwa P, et al
    Diagnostic accuracy of multiparametric MRI for detecting unconventional prostate cancer histology: a systematic review and meta-analysis.
    Eur Radiol. 2025 Apr 30. doi: 10.1007/s00330-025-11603.
    >> Share

  23. AGROTIS G, Pooch EP, Marsitopoulos K, Vlychou M, et al
    Detection rates for prostate cancer using PI-RADS 2.1 upgrading rules in transition zone lesions align with risk assessment categories: a systematic review and meta-analysis.
    Eur Radiol. 2025 Apr 27. doi: 10.1007/s00330-025-11618.
    >> Share

  24. AZMA YN, Boci N, Abramowicz K, Russo L, et al
    Influence of imaging method on fat fraction estimation for assessing bone marrow in metastatic prostate cancer.
    Eur Radiol. 2025 Apr 11. doi: 10.1007/s00330-025-11564.
    >> Share

  25. NAVES AA, Gouvea GL, Machado CVB, Colli LM, et al
    MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
    Eur Radiol. 2025 Apr 5. doi: 10.1007/s00330-025-11532.
    >> Share

  26. MAFFEI D, Moore CM
    Personalized risk-adapted models in prostate cancer during active surveillance using MRI-a narrative review.
    Eur Radiol. 2025 Apr 4. doi: 10.1007/s00330-025-11518.
    >> Share

  27. CAMPBELL RA, Wood A, Schwen Z, Ward R, et al
    MRI and active surveillance: thoughts from across the pond.
    Eur Radiol. 2025;35:2157-2169.
    >> Share

    March 2025
  28. EVANGELISTA L, Vallone C, Guglielmo P
    Optimizing prostate cancer diagnosis: combining imaging modalities for tailored treatment.
    Eur Radiol. 2025 Mar 25. doi: 10.1007/s00330-025-11551.
    >> Share

  29. WOO S, Becker AS, Leithner D, Charbel C, et al
    PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.
    Eur Radiol. 2025 Mar 20. doi: 10.1007/s00330-025-11514.
    >> Share

  30. PADHANI AR, Papanikolaou N
    AI and human interactions in prostate cancer diagnosis using MRI.
    Eur Radiol. 2025 Mar 7. doi: 10.1007/s00330-025-11498.
    >> Share

    February 2025
  31. GIGANTI F, Moreira da Silva N, Yeung M, Davies L, et al
    AI-powered prostate cancer detection: a multi-centre, multi-scanner validation study.
    Eur Radiol. 2025 Feb 28. doi: 10.1007/s00330-024-11323.
    >> Share

  32. HAIDER MA
    PI-CAI: a landmark AI study for prostate cancer detection on MRI.
    Eur Radiol. 2025 Feb 17. doi: 10.1007/s00330-025-11454.
    >> Share

    January 2025
  33. PANEBIANCO V, Catalano C, Sanguedolce F, De Santis M, et al
    ESR Bridges: next-generation imaging in prostate cancer-a multidisciplinary view.
    Eur Radiol. 2025 Jan 31. doi: 10.1007/s00330-025-11354.
    >> Share

  34. KLEIBURG F, de Geus-Oei LF, Spijkerman R, Noortman WA, et al
    Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients.
    Eur Radiol. 2025 Jan 22. doi: 10.1007/s00330-025-11360.
    >> Share

    December 2024
  35. CAVALLO AU, Stanzione A, Ponsiglione A, Trotta R, et al
    Prostate cancer MRI methodological radiomics score: a EuSoMII radiomics auditing group initiative.
    Eur Radiol. 2024 Dec 30. doi: 10.1007/s00330-024-11299.
    >> Share

  36. DEBS N, Routier A, Bone A, Rohe MM, et al
    Evaluation of a deep learning prostate cancer detection system on biparametric MRI against radiological reading.
    Eur Radiol. 2024 Dec 19. doi: 10.1007/s00330-024-11287.
    >> Share

  37. BAUCKNEHT M, Laudicella R, Lanfranchi F, Ciccarese C, et al
    PSMA PET/CT in staging recurrent prostate cancer: a viewfinder, not a compass.
    Eur Radiol. 2024 Dec 18. doi: 10.1007/s00330-024-11297.
    >> Share

  38. BAUCKNEHT M, Laudicella R, Lanfranchi F, Burger IA, et al
    Unspecific bone uptakes in PSMA PET for prostate cancer: why do they matter?
    Eur Radiol. 2024 Dec 4. doi: 10.1007/s00330-024-11252.
    >> Share

  39. DIAS AB, Woo S, Leni R, Rajwa P, et al
    Is MRI ready to replace biopsy during active surveillance?
    Eur Radiol. 2024;34:7716-7727.
    >> Share

  40. BOZGO V, Roest C, van Oort I, Yakar D, et al
    Prostate MRI and artificial intelligence during active surveillance: should we jump on the bandwagon?
    Eur Radiol. 2024;34:7698-7704.
    >> Share

    November 2024
  41. RATA M, Orton MR, Tunariu N, Curcean A, et al
    Repeatability of quantitative MR fingerprinting for T(1) and T(2) measurements of metastatic bone in prostate cancer patients.
    Eur Radiol. 2024 Nov 6. doi: 10.1007/s00330-024-11162.
    >> Share

  42. DE ROOIJ M, Allen C, Twilt JJ, Thijssen LCP, et al
    PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI.
    Eur Radiol. 2024;34:7068-7079.
    >> Share

  43. PONSIGLIONE A, Brembilla G, Cuocolo R, Gutierrez P, et al
    ESR Essentials: using the right scoring system in prostate MRI-practice recommendations by ESUR.
    Eur Radiol. 2024;34:7481-7491.
    >> Share

  44. VAN LOHUIZEN Q, Roest C, Simonis FFJ, Fransen SJ, et al
    Assessing deep learning reconstruction for faster prostate MRI: visual vs. diagnostic performance metrics.
    Eur Radiol. 2024;34:7364-7372.
    >> Share

    October 2024
  45. HAMM CA, Baumgartner GL, Padhani AR, Frobose KP, et al
    Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies.
    Eur Radiol. 2024;34:6229-6240.
    >> Share

  46. MARVASO G, Isaksson LJ, Zaffaroni M, Vincini MG, et al
    Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models.
    Eur Radiol. 2024;34:6241-6253.
    >> Share

    September 2024
  47. BOSCHHEIDGEN M, Schimmoller L, Radtke JP, Kastl R, et al
    MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.
    Eur Radiol. 2024 Sep 13. doi: 10.1007/s00330-024-11062.
    >> Share

    August 2024
  48. FRANSEN SJ, Kwee TC, Rouw D, Roest C, et al
    Patient perspectives on the use of artificial intelligence in prostate cancer diagnosis on MRI.
    Eur Radiol. 2024 Aug 14. doi: 10.1007/s00330-024-11012.
    >> Share

  49. ISRAEL B
    From data to decisions: deep learning is shaping prostate cancer diagnostics.
    Eur Radiol. 2024 Aug 2. doi: 10.1007/s00330-024-10997.
    >> Share

    July 2024
  50. AGROTIS G, Pooch E, Abdelatty M, Benson S, et al
    Diagnostic performance of ADC and ADCratio in MRI-based prostate cancer assessment: A systematic review and meta-analysis.
    Eur Radiol. 2024 Jul 12. doi: 10.1007/s00330-024-10890.
    >> Share

  51. SCHRADER A, Netzer N, Hielscher T, Gortz M, et al
    Prostate cancer risk assessment and avoidance of prostate biopsies using fully automatic deep learning in prostate MRI: comparison to PI-RADS and integration with clinical data in nomograms.
    Eur Radiol. 2024 Jul 2. doi: 10.1007/s00330-024-10818.
    >> Share

  52. STANZIONE A, Lee KL, Sanmugalingam N, Rajendran I, et al
    Expect the unexpected: investigating discordant prostate MRI and biopsy results.
    Eur Radiol. 2024;34:4810-4820.
    >> Share

  53. LANGKILDE F, Masaba P, Edenbrandt L, Gren M, et al
    Manual prostate MRI segmentation by readers with different experience: a study of the learning progress.
    Eur Radiol. 2024;34:4801-4809.
    >> Share

    June 2024
  54. PADHANI AR, Tunariu N, Perez-Lopez R, Tombal B, et al
    Evaluating prostate cancer bone metastases response with whole-body MRI: What we know and still need to know.
    Eur Radiol. 2024 Jun 20. doi: 10.1007/s00330-024-10864.
    >> Share

  55. NAKAI H, Suman G, Adamo DA, Navin PJ, et al
    Natural language processing pipeline to extract prostate cancer-related information from clinical notes.
    Eur Radiol. 2024 Jun 6. doi: 10.1007/s00330-024-10812.
    >> Share

  56. PONSIGLIONE A, Gambardella M, Stanzione A, Green R, et al
    Radiomics for the identification of extraprostatic extension with prostate MRI: a systematic review and meta-analysis.
    Eur Radiol. 2024;34:3981-3991.
    >> Share

    May 2024
  57. OERTHER B, Engel H, Nedelcu A, Strecker R, et al
    Performance of an ultra-fast deep-learning accelerated MRI screening protocol for prostate cancer compared to a standard multiparametric protocol.
    Eur Radiol. 2024 May 23. doi: 10.1007/s00330-024-10776.
    >> Share

  58. BREMBILLA G, Giganti F
    Improving image quality in prostate MRI: the time is now.
    Eur Radiol. 2024;34:3385-3386.
    >> Share

  59. NAKAI H, Takahashi H, Adamo DA, LeGout JD, et al
    Decreased prostate MRI cancer detection rate due to moderate to severe susceptibility artifacts from hip prosthesis.
    Eur Radiol. 2024;34:3387-3399.
    >> Share

    April 2024
  60. MUGLIA VF
    Refining clinical decision strategies and prostate cancer detection through fine adjustments in the combination of PSA-derived parameters and MRI.
    Eur Radiol. 2024 Apr 29. doi: 10.1007/s00330-024-10734.
    >> Share

  61. CAGLIC I, Sushentsev N, Syer T, Lee KL, et al
    Biparametric MRI in prostate cancer during active surveillance: is it safe?
    Eur Radiol. 2024 Apr 24. doi: 10.1007/s00330-024-10770.
    >> Share

  62. BOELLAARD TN, van Dijk-de Haan MC, Heijmink SWTPJ, Tillier CN, et al
    Membranous urethral length measurement on preoperative MRI to predict incontinence after radical prostatectomy: a literature review towards a proposal for measurement standardization.
    Eur Radiol. 2024;34:2621-2640.
    >> Share

    March 2024
  63. GIROMETTI R, Giganti F
    Active surveillance of prostate cancer: MRI and beyond.
    Eur Radiol. 2024 Mar 28. doi: 10.1007/s00330-024-10717.
    >> Share

    February 2024
  64. PADHANI AR, Godtman RA, Schoots IG
    Key learning on the promise and limitations of MRI in prostate cancer screening.
    Eur Radiol. 2024 Feb 5. doi: 10.1007/s00330-024-10626.
    >> Share

    January 2024
  65. MAZZETTI S, Defeudis A, Nicoletti G, Chiorino G, et al
    Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer.
    Eur Radiol. 2024 Jan 4. doi: 10.1007/s00330-023-10542.
    >> Share

  66. PANEBIANCO V
    Prostate cancer imaging for primary detection: PSMA-PET/CT vs MRI. All that glitters is not gold.
    Eur Radiol. 2024 Jan 2. doi: 10.1007/s00330-023-10547.
    >> Share

    December 2023
  67. EVANGELISTA L, Filippi L
    Structured reporting in prostate cancer: the revolution of quality in nuclear medicine scan interpretation.
    Eur Radiol. 2023 Dec 20. doi: 10.1007/s00330-023-10507.
    >> Share

  68. NOTO B, Eveslage M, Auf der Springe K, Exler A, et al
    Robustness of apparent diffusion coefficient-based lymph node classification for diagnosis of prostate cancer metastasis.
    Eur Radiol. 2023 Dec 15. doi: 10.1007/s00330-023-10406.
    >> Share

  69. JANNUSCH K, Bruckmann NM, Morawitz J, Boschheidgen M, et al
    Recurrent prostate cancer: combined role for MRI and PSMA-PET in (68)Ga-PSMA-11 PET/MRI.
    Eur Radiol. 2023 Dec 1. doi: 10.1007/s00330-023-10442.
    >> Share

  70. ROUVIERE O
    Contrast-medium administration for prostate MRI can be abandoned: no(t so simple)!
    Eur Radiol. 2023;33:8415-8416.
    >> Share

  71. ASBACH P
    Contrast-medium administration for prostate MRI: yes! Contrast-medium administration can be abandoned.
    Eur Radiol. 2023;33:8413-8414.
    >> Share

    November 2023
  72. MA J, Yang Q, Ye X, Xu W, et al
    Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis.
    Eur Radiol. 2023 Nov 20. doi: 10.1007/s00330-023-10436.
    >> Share

  73. NETZER N, Eith C, Bethge O, Hielscher T, et al
    Application of a validated prostate MRI deep learning system to independent same-vendor multi-institutional data: demonstration of transferability.
    Eur Radiol. 2023;33:7463-7476.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016